UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 646

Sortiert nach

Rituximab: Mechanism of Action

Seminars in hematology, 2010-04, Vol.47 (2), p.115-123

Weiner, George J

2010

Volltextzugriff (PDF)

Immune checkpoint markers and anti‐CD20‐mediated NK cell activation

Journal of leukocyte biology, 2021-10, Vol.110 (4), p.723-733

2021

Volltextzugriff (PDF)

T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.237-249

2022

Volltextzugriff (PDF)

Complement in monoclonal antibody therapy of cancer

Immunologic research, 2014-08, Vol.59 (1-3), p.203-210

2014

Volltextzugriff (PDF)

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer

BMC cancer, 2021-07, Vol.21 (1), p.1-14, Article 808

2021

Volltextzugriff (PDF)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Journal of hematology and oncology, 2021-12, Vol.14 (1), p.204-204, Article 204

2021

Volltextzugriff (PDF)

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Blood, 2024-05, Vol.143 (18), p.1816

2024

Volltextzugriff (PDF)

Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential Biomarkers

Cancers, 2020-10, Vol.12 (10), p.2956

2020

Volltextzugriff (PDF)

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2010-09, Vol.28 (27), p.4191-4198

2010

Volltextzugriff (PDF)

Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer

Annals of surgical oncology, 2021-02, Vol.28 (2), p.1187-1197

2021

Volltextzugriff (PDF)

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Clinical cancer research, 2008-10, Vol.14 (20), p.6697-6703

2008

Volltextzugriff (PDF)

CpG oligodeoxynucleotide-based therapy of lymphoid malignancies

Advanced drug delivery reviews, 2009-03, Vol.61 (3), p.263-267

Weiner, George J.

2009

Volltextzugriff (PDF)

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

Blood, 2011-09, Vol.118 (12), p.3347-3349

2011

Volltextzugriff (PDF)

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

Scientific reports, 2021-01, Vol.11 (1), p.1535-11, Article 1535

2021

Volltextzugriff (PDF)

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

Blood, 2009-12, Vol.114 (26), p.5322-5330

2009

Volltextzugriff (PDF)

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

Leukemia & lymphoma, 2013-11, Vol.54 (11), p.2500-2505

2013

Volltextzugriff (PDF)

Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer

The AAPS journal, 2015-01, Vol.17 (1), p.184-193

2015

Volltextzugriff (PDF)

Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion

Blood, 2010-02, Vol.115 (6), p.1156-1165

2010

Volltextzugriff (PDF)

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors

Cancers, 2023-10, Vol.15 (20), p.4913

2023

Volltextzugriff (PDF)

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Blood, 2011-02, Vol.117 (5), p.1492-1498

2011

Volltextzugriff (PDF)

Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma

Journal of cellular biochemistry, 2012-02, Vol.113 (2), p.419-425

2012

Volltextzugriff (PDF)

A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors

Cancer immunology research, 2020-09, Vol.8 (9), p.1206-1214

2020

Volltextzugriff (PDF)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

Haematologica (Roma), 2018-02, Vol.103 (2), p.297

2018

Volltextzugriff (PDF)

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy

Clinical cancer research, 2017-02, Vol.23 (4), p.954-961

2017

Volltextzugriff (PDF)

AACR Cancer Progress Report 2013

Clinical cancer research, 2013-10, Vol.19 (20 Suppl), p.S4-S98

2013

Volltextzugriff (PDF)

1 – 25 von 646

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(563)
Mit Volltextzugriff
(563)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(641)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(64)
Cancer Research
(23)
Journal Of Clinical Oncology
(18)
American Journal Of Obstetrics And Gynecology
(16)
The Journal Of Immunology
(12)
Vaccine
(12)
Journal For Immunotherapy Of Cancer
(11)
Alzheimer's & Dementia
(10)
Clinical Cancer Research
(10)
Nature Communications
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Rituximab: Mechanism of Action

Immune checkpoint markers and anti‐CD20‐mediated NK cell activation

T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity

Complement in monoclonal antibody therapy of cancer

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential Biomarkers

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma

Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

CpG oligodeoxynucleotide-based therapy of lymphoid malignancies

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer

Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma

A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy

AACR Cancer Progress Report 2013

Aktive Filter

Suchergebnisse filtern